Breaking & Recent News Talphera Inc TLPH

Healthcare

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TLPH)

AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain

PR Newswire December 13, 2016

AcelRx Pharmaceuticals Reports on ARX-04 Market and Landscape Presented at Analyst & Investor Event

PR Newswire December 6, 2016

AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain

PR Newswire November 28, 2016

AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting

PR Newswire November 17, 2016

AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016

PR Newswire November 9, 2016

AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in November

PR Newswire November 8, 2016

AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016 Financial Results

PR Newswire November 1, 2016

AcelRx Pharmaceuticals to Present ARX-04 Analysis for Treatment of Moderate-to-Severe Acute Pain in Obese Patients at The Obesity Society Annual Meeting

PR Newswire October 31, 2016

AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Tuesday, November 1st, 2016

PR Newswire October 25, 2016

AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings at National Conference on Correctional Health Care

PR Newswire October 24, 2016

AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine

PR Newswire September 28, 2016

AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain

PR Newswire September 27, 2016

Findings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting

PR Newswire September 22, 2016

AcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference

PR Newswire September 22, 2016